Product image of Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle‑Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin (biologic) presented as a biologic injectable for intramuscular or subcutaneous use. It treats infertility caused by anovulation and is employed in controlled ovarian stimulation for assisted reproductive technologies. It is indicated for women undergoing fertility treatment cycles.

GNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Manufacturer / TM Owner

Ibsa Slovakia S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Meriofert is a gonadotropin used in reproductive medicine to stimulate ovarian follicle development.
  • Anovulatory infertility: promotes follicular growth to enable ovulation
  • Controlled ovarian stimulation for IVF: enhances multiple follicle development for egg retrieval
  • Assisted reproductive technology cycles: improves ovarian response to achieve higher success rates
  • Ovarian stimulation in intrauterine insemination (IUI): increases number of mature oocytes
  • Ovulation induction in polycystic ovary syndrome (PCOS): facilitates regular ovulation

How It Works

  • Meriofert contains recombinant follicle‑stimulating hormone and luteinising hormone that bind to their respective FSH and LH receptors on ovarian granulosa and theca cells. Activation of these receptors stimulates intracellular cAMP signaling, leading to follicular maturation, estrogen synthesis, and the LH‑triggered ovulatory cascade. The combined action supports the development of multiple follicles and prepares the ovary for oocyte release during assisted reproductive procedures.

Side Effects

Meriofert may be associated with a range of adverse reactions following injection.

Common Side Effects

  • Injection site pain: mild discomfort at the injection site.
  • Bruising or hematoma: localized bleeding under the skin.
  • Abdominal discomfort: mild pelvic pain or bloating.
  • Nausea: transient feeling of sickness.
  • Headache: mild to moderate tension‑type headache.
  • Mild ovarian hyperstimulation syndrome: mild abdominal distension and weight gain.

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, respiratory distress.
  • Multiple pregnancy: increased risk of twins or higher‑order gestations.
  • Allergic reaction or anaphylaxis: rash, itching, swelling, difficulty breathing.
  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Ectopic pregnancy: implantation outside the uterine cavity.

Precautions & Warnings

When using Meriofert, clinicians should observe several precautionary measures to minimise risks.

  • Monitor ovarian response: perform serial ultrasound and estradiol measurements.
  • Avoid in patients with ovarian cysts or tumors: risk of exacerbation.
  • Use caution in hypersensitive individuals: discontinue if allergic signs appear.
  • Assess pregnancy status: not indicated for use during established pregnancy.
  • Discuss risk of multiple gestation: counsel patients on potential outcomes.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert can interact with other medications that affect ovarian stimulation or hormonal balance.

Major Interactions (Avoid)

  • GnRH agonists: may cause excessive ovarian stimulation when combined.
  • Estrogen‑containing contraceptives: reduce the efficacy of Meriofert.
  • Thyroid hormone therapy: altered response may occur.
  • Anticoagulants: increased risk of ovarian bleeding.

Moderate Interactions (Monitor Closely)

  • Clomiphene citrate: additive stimulation may increase OHSS risk.
  • Letrozole: may enhance follicular response, requiring dose adjustment.
  • Metformin: can modify ovarian sensitivity in PCOS patients.
  • Other gonadotropins: cumulative effect may lead to over‑stimulation.

Frequently Asked Questions

Meriofert is prescribed to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies such as in‑vitro fertilisation, intrauterine insemination and ovulation induction protocols.

The recombinant FSH and LH in Meriofert bind to their specific receptors on ovarian granulosa and theca cells. This triggers intracellular signalling that promotes follicle growth, estrogen production and the LH‑mediated ovulatory surge, enabling the development of mature oocytes for retrieval.

The dose of Meriofert is individualized by the treating physician based on the patient’s ovarian reserve, stimulation protocol and response monitoring. No fixed regimen is provided; the prescriber determines the appropriate amount and schedule.

Meriofert is not indicated for use during an established pregnancy, and safety data for breastfeeding are limited. It should be discontinued once pregnancy is confirmed, and women should discuss breastfeeding considerations with their healthcare provider.

To request Meriofert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meriofert combines recombinant FSH and LH in a single formulation, whereas some alternatives provide only FSH or use urinary‑derived preparations. The combined product can simplify dosing and may offer more consistent bioactivity, but choice depends on individual patient response, protocol preferences and cost considerations.

Meriofert must be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Prior to use, allow the vial to reach room temperature if required, and follow aseptic technique for reconstitution and injection.

Meriofert is supplied for injection and may be given either intramuscularly or subcutaneously according to the prescribing clinician’s instructions. The injection is typically performed using a sterile syringe and needle, with the site rotated to minimise local reactions.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, fluid accumulation and respiratory compromise, as well as multiple pregnancy and rare allergic reactions such as anaphylaxis. Prompt medical attention is required if these events occur.

Meriofert is contraindicated in patients with known hypersensitivity to gonadotropins, active ovarian cysts or tumors, uncontrolled thyroid disease, and in women who are already pregnant. Caution is also advised for individuals with a history of thromboembolic disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT